Dr. Neha Mehta-shah, M.D.
Claim this profileWashington University School of Medicine
About Neha Mehta-shah, M.D.
Education:
- MD from Feinberg School of Medicine, Northwestern University, Chicago, IL (2005-2009).
- Masters of Science in Clinical Investigation (MSCI) from Washington University in St. Louis, MO (2016-2019).
- BA in Psychology (Cum Laude) from Northwestern University, Evanston, IL (2002-2005).
Experience:
- Assistant Professor of Medicine at Washington University in St. Louis, specializing in peripheral and cutaneous T-cell lymphomas.
- Fellow in Hematology/Oncology at Memorial Sloan Kettering Cancer Center, New York, NY (2013-2016).
- Chief Medical Resident at Memorial Sloan Kettering Cancer Center, New York, NY (2012-2013).
- Resident in Internal Medicine at New York Presbyterian-Weill Cornell Medical Center, New York, NY (2009-2012).
Area of expertise
Lymphoma
Neha Mehta-shah, M.D. has run 7 trials for Lymphoma. Some of their research focus areas include:
Sezary Syndrome
Neha Mehta-shah, M.D. has run 5 trials for Sezary Syndrome. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Siteman Cancer Center At West County Hospital
Clinical Trials Neha Mehta-shah, M.D. is currently running
Thiotepa + Stem Cell Transplant
for Lymphoma
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk. Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma. The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration. This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.
Recruiting
1 award
Phase 2
3 criteria
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting
1 award
Phase 2
27 criteria
More about Neha Mehta-shah, M.D.
Clinical Trial Related
5 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Neha Mehta-shah, M.D. has experience with
- Nivolumab
- Rituximab
- Duvelisib
- Mosunetuzumab
- Acalabrutinib
- Durvalumab
Breakdown of trials Neha Mehta-shah, M.D. has run
Lymphoma
Sezary Syndrome
Non-Hodgkin's Lymphoma
Mycosis Fungoides/Sezary Syndrome
Cutaneous T-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Neha Mehta-shah, M.D. specialize in?
Neha Mehta-shah, M.D. focuses on Lymphoma and Sezary Syndrome. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are CD7 positive.
Is Neha Mehta-shah, M.D. currently recruiting for clinical trials?
Yes, Neha Mehta-shah, M.D. is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Neha Mehta-shah, M.D. has studied deeply?
Yes, Neha Mehta-shah, M.D. has studied treatments such as Nivolumab, Rituximab, Duvelisib.
What is the best way to schedule an appointment with Neha Mehta-shah, M.D.?
Apply for one of the trials that Neha Mehta-shah, M.D. is conducting.
What is the office address of Neha Mehta-shah, M.D.?
The office of Neha Mehta-shah, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.